- Home
- STTK vs MASK Comparison
STTK vs MASK Comparison
Compare STTK & MASK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- MASK
- Stock Information
- Founded
- STTK 2016
- MASK 2017
- Country
- STTK United States
- MASK China
- Employees
- STTK N/A
- MASK N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- MASK
- Sector
- STTK Health Care
- MASK
- Exchange
- STTK Nasdaq
- MASK NYSE
- Market Cap
- STTK 37.6M
- MASK 36.3M
- IPO Year
- STTK 2020
- MASK 2025
- Fundamental
- Price
- STTK $1.14
- MASK $3.15
- Analyst Decision
- STTK Hold
- MASK
- Analyst Count
- STTK 4
- MASK 0
- Target Price
- STTK $3.00
- MASK N/A
- AVG Volume (30 Days)
- STTK 101.1K
- MASK 51.7K
- Earning Date
- STTK 07-31-2025
- MASK 01-01-0001
- Dividend Yield
- STTK N/A
- MASK N/A
- EPS Growth
- STTK N/A
- MASK 12.16
- EPS
- STTK N/A
- MASK 0.19
- Revenue
- STTK $4,606,000.00
- MASK $4,718,055.00
- Revenue This Year
- STTK N/A
- MASK N/A
- Revenue Next Year
- STTK N/A
- MASK N/A
- P/E Ratio
- STTK N/A
- MASK $16.03
- Revenue Growth
- STTK 69.65
- MASK 7.89
- 52 Week Low
- STTK $0.69
- MASK $2.50
- 52 Week High
- STTK $7.49
- MASK $4.19
- Technical
- Relative Strength Index (RSI)
- STTK 56.02
- MASK N/A
- Support Level
- STTK $0.98
- MASK N/A
- Resistance Level
- STTK $1.13
- MASK N/A
- Average True Range (ATR)
- STTK 0.10
- MASK 0.00
- MACD
- STTK 0.01
- MASK 0.00
- Stochastic Oscillator
- STTK 84.85
- MASK 0.00
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About MASK 3 E NETWORK TECHNOLOGY GROUP LTD
3 E Network Technology Group Ltd is a business-to-business (B2B) information technology (IT) business solutions provider. It focuses on integrated software and hardware solutions in the property management and exhibition services spaces and expanded software solutions offering to a variety of industries and sectors, including food establishments, real estate, exhibition & conferencing, and clean energy utilities. The business includes two main portfolios, namely the software development portfolio and exhibition and conference portfolio. Maximum revenue is generated from the software development portfolio.